Slide background

We are

builders

Slide background

We focus on

highly innovative science

Slide background

We leverage

on our unique model

 

MISSION AND STRATEGY

Eclosion Ventures manages the Eclosion life science investment fund, which focuses on translating cutting edge science into biotechnology companies developing transformational best-in-diseases therapeutics and platform technologies.

We are builders. Eclosion's approach is defined by its unique entrepreneurial mindset leading to a strong operational and investment commitment to start-up enterprises. Eclosion is driven by an experienced management team which brings together scientific, operational and financial expertise and a successful track record of company creation, value generation and development of new therapeutics that will transform human healthcare.

We focus on highly innovative science and early stage companies developing new approaches to address high unmet medical needs. Eclosion2 fund’s portfolio companies have developed first-in-class drugs with high potential value to patients in fields such as multiple sclerosis, fibrosis or oncology.

We leverage on our unique Model. Eclosion brings together public enterprise and private venture capital through the combination, under a common management, of the Eclosion Foundation, a life science accelerator platform, and Eclosion Ventures, managing Eclosion’s private investment fund, which invests at seed and capital stage up to clinical proof of concept, making significant long term operational and financial commitments to portfolio companies, with the potential to change the way patients are treated.

  • “The progress of GeNeuro from the initial discovery of the link between Human Endogenous RetroViruses and Multiple Sclerosis to the signature of our licensing agreement with Servier would not have been possible without the scientific belief and long-term support of Eclosion”

    Hervé Perron
    Hervé Perron, Founder of GeNeuro
  •  

    “Eclosion’s operational and financial commitments were essential in translating the initial NOX enzyme discoveries into a clinical stage company that has gone on to receive significant private investment”

    Karl-Heinz Krause
    Karl-Heinz Krause, Founder of GenKyoTex

LEADERSHIP

   
   

SPECIAL ADVISOR

BOARD OF DIRECTORS

 

 

A PORTFOLIO WITH OUTSTANDING POTENTIAL

  • All
  • GENEURO

    Novel therapeutic with potential to halt progression in Multiple Sclerosis
    Innovation : First Company to develop targeted therapies against Human Endogenous Retrovirus mediated diseases


    VISIT WEBSITE

  • GENKYOTEX

    Novel therapeutic approach to treat oxygen radical-mediated pathologies common to most age-related degenerative diseases
    Innovation: First company to develop targeted therapies through the effective inhibition of specific NADPH oxidase enzymes

    Founding scientists: Spin-off from top Universities: Geneva (CH), Kyoto (J), San Antonio /Texas and Emory/Atlanta (USA).


    VISIT WEBSITE

  • DepGen – NETRIS PHARMA

    Novel therapeutic approach in oncology based on dependence receptors and their impact on cell proliferation
    Innovation: First company to develop cancer therapies through targeting dependence receptors


    VISIT WEBSITE

LATEST NEWS

GeNeuro and Servier Announce Promising post hoc Analyses of Six-Month Data from CHANGE-MS Phase 2b Study at MSParis2017

Geneva, Switzerland, and Paris, France, October 28, 2017 – 11:00 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced ...

GeNeuro and Collaborators Publish Data Supporting Role of Retroviral Pathogenic Envelope Protein in Type 1 Diabetes (T1D)

Geneva, Switzerland, 11 September 2017 – 07:30 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing ...

GeNeuro and Servier Announce Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis

Geneva, Switzerland, and Paris, France, 28 August 2017 – 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced ...

CONTACT US